Institute for Follicular Lymphoma Innovation
Overview
Institute for Follicular Lymphoma Innovation is a global, non-profit, private foundation that deploys its budget across grants, project-based partnerships, and venture philanthropy investments to accelerate the development of innovative treatment options for patients with follicular lymphoma.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| LTZ Therapeutics | Apr 2025 | Series A Extension | Co-investor |
| NanoCell Therapeutics | Jun 2025 | Seed | Co-investor |
| PeproMene Bio | Dec 2024 | Corporate Funding | Lead |
| Enterome | Jun 2025 | VC Round | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Institute for Follicular Lymphoma Innovation based?
Institute for Follicular Lymphoma Innovation is headquartered in Diamond Bar, California, United States.
When was Institute for Follicular Lymphoma Innovation founded?
Institute for Follicular Lymphoma Innovation was founded in 2022.
How many portfolio companies does Institute for Follicular Lymphoma Innovation have?
Institute for Follicular Lymphoma Innovation has 4 portfolio companies in Caplight's dataset.
What are some companies in Institute for Follicular Lymphoma Innovation's portfolio?
Portfolio companies visible on Caplight include LTZ Therapeutics, NanoCell Therapeutics, PeproMene Bio, Enterome.
What was Institute for Follicular Lymphoma Innovation's most recent investment shown here?
Institute for Follicular Lymphoma Innovation's most recent investment in this portfolio sample was in NanoCell Therapeutics in 2025.
What sectors does Institute for Follicular Lymphoma Innovation focus on?
Institute for Follicular Lymphoma Innovation focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Institute for Follicular Lymphoma Innovation focus on?
Institute for Follicular Lymphoma Innovation typically invests at the Late stage.